Positive News SentimentPositive NewsNASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free IMNM Stock Alerts $13.28 +0.13 (+0.99%) (As of 04:26 PM ET) Add Compare Share Share Today's Range$12.81▼$13.4750-Day Range$13.15▼$21.0252-Week Range$5.26▼$30.96Volume969,309 shsAverage Volume762,346 shsMarket Capitalization$796.39 millionP/E RatioN/ADividend YieldN/APrice Target$29.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunome alerts: Email Address Immunome MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.4% Upside$29.80 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment1.52Based on 3 Articles This WeekInsider TradingAcquiring Shares$27,140 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.45) to ($2.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.99 out of 5 starsMedical Sector618th out of 913 stocksPharmaceutical Preparations Industry291st out of 430 stocks 3.5 Analyst's Opinion Consensus RatingImmunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunome has only been the subject of 4 research reports in the past 90 days.Read more about Immunome's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IMNM. Previous Next 0.0 Dividend Strength Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNM. Previous Next 3.6 News and Social Media Coverage News SentimentImmunome has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Immunome this week, compared to 2 articles on an average week.Search Interest9 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,140.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunome are expected to decrease in the coming year, from ($1.45) to ($2.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Immunome Stock (NASDAQ:IMNM)Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Read More IMNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNM Stock News HeadlinesMay 23, 2024 | insidertrades.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Buys 2,000 Shares of StockJune 16 at 5:16 AM | americanbankingnews.comImmunome (NASDAQ:IMNM) Shares Down 7.7% June 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.June 8, 2024 | americanbankingnews.comImmunome (NASDAQ:IMNM) Shares Down 4.2% May 24, 2024 | msn.comImmunome (NASDAQ:IMNM): An Opportunity for Investors with Strong StomachsMay 21, 2024 | finance.yahoo.comInsider Buying: Immunome Inc's CEO Acquires 100,000 SharesMay 20, 2024 | businesswire.comImmunome Announces Completion of Purchase of Assets from AtrecaMay 17, 2024 | msn.comImmunome appoints CFOJune 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.May 17, 2024 | businesswire.comImmunome Announces Promotion of Max Rosett to Chief Financial OfficerMay 16, 2024 | markets.businessinsider.comImmunome’s Promising Pipeline and Strategic Positioning Affirm Buy RatingMay 14, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | markets.businessinsider.comImmunome, Inc. Q1 Loss Increases, Misses EstimatesMay 14, 2024 | businesswire.comImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | businesswire.comImmunome to Present at 2024 Bank of America Healthcare ConferenceMay 2, 2024 | businesswire.comImmunome Appoints Kinney Horn as Chief Business OfficerApril 25, 2024 | businesswire.comImmunome Appoints Sandra M. Swain to Board of DirectorsApril 19, 2024 | finance.yahoo.comImmunome, Inc. (IMNM)April 17, 2024 | msn.comImmunome (IMNM) Price Target Increased by 8.72% to 36.04April 16, 2024 | msn.comGuggenheim Initiates Coverage of Immunome (IMNM) with Buy RecommendationApril 5, 2024 | businesswire.comImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 29, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)March 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 27, 2024 | finance.yahoo.comImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaMarch 22, 2024 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutionsSee More Headlines Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/18/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNM CUSIPN/A CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$29.80 High Stock Price Target$35.00 Low Stock Price Target$24.00 Potential Upside/Downside+123.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($7.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,810,000.00 Net Margins-1,829.44% Pretax Margin-1,829.44% Return on Equity-37.33% Return on Assets-26.06% Debt Debt-to-Equity RatioN/A Current Ratio10.18 Quick Ratio10.18 Sales & Book Value Annual Sales$12.68 million Price / Sales62.98 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book4.81Miscellaneous Outstanding Shares59,969,000Free Float54,812,000Market Cap$798.79 million OptionableOptionable Beta1.85 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Clay B. Siegall Ph.D. (Age 63)President, CEO & Chairman Comp: $1.43MDr. Jack Higgins Ph.D. (Age 44)Chief Scientific Officer Comp: $956.34kDr. Robert J. Lechleider M.D. (Age 63)Chief Medical Officer Comp: $512.49kKey CompetitorsVir BiotechnologyNASDAQ:VIRIGM BiosciencesNASDAQ:IGMSAimmune TherapeuticsNASDAQ:AIMTCrinetics PharmaceuticalsNASDAQ:CRNXAxsome TherapeuticsNASDAQ:AXSMView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 594,000 shares on 5/24/2024Ownership: 0.990%Cetera Investment AdvisersBought 123,098 shares on 5/24/2024Ownership: 0.205%Jean Jacques BienaimeBought 2,000 shares on 5/21/2024Total: $27,140.00 ($13.57/share)Zimmer Partners LPBought 75,000 shares on 5/17/2024Ownership: 0.125%Janus Henderson Group PLCBought 146,943 shares on 5/16/2024Ownership: 2.567%View All Insider TransactionsView All Institutional Transactions IMNM Stock Analysis - Frequently Asked Questions Should I buy or sell Immunome stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNM shares. View IMNM analyst ratings or view top-rated stocks. What is Immunome's stock price target for 2024? 7 brokerages have issued 12-month price targets for Immunome's shares. Their IMNM share price targets range from $24.00 to $35.00. On average, they predict the company's stock price to reach $29.80 in the next twelve months. This suggests a possible upside of 124.4% from the stock's current price. View analysts price targets for IMNM or view top-rated stocks among Wall Street analysts. How have IMNM shares performed in 2024? Immunome's stock was trading at $10.70 at the start of the year. Since then, IMNM shares have increased by 24.1% and is now trading at $13.28. View the best growth stocks for 2024 here. When is Immunome's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our IMNM earnings forecast. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) announced its earnings results on Tuesday, May, 14th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.46. The business earned $1.03 million during the quarter, compared to analyst estimates of $4 million. Immunome had a negative trailing twelve-month return on equity of 37.33% and a negative net margin of 1,829.44%. What ETFs hold Immunome's stock? ETFs with the largest weight of Immunome (NASDAQ:IMNM) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). When did Immunome IPO? Immunome (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO. Who are Immunome's major shareholders? Immunome's stock is owned by a variety of institutional and retail investors. Top institutional investors include Redmile Group LLC (8.16%), Price T Rowe Associates Inc. MD (3.75%), Vanguard Group Inc. (3.37%), Janus Henderson Group PLC (2.57%), Farallon Capital Management LLC (0.99%) and Lord Abbett & CO. LLC (0.74%). Insiders that own company stock include Bruce Turner, Clay B Siegall, Jean Jacques Bienaime and Michael Rapp. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNM) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
